Androxal has predicted cost of $2000 per year !

Assuming a conservative addressable market of just 350,000 men for Androxal for the treatment of secondary hypogonadism, the potential market size could be in excess of $700 million annually based on an annual treatment cost of $2,000 per patient. Meanwhile, the company anticipates capturing a large portion of the market given its oral treatment with no black box warnings, no partner risk, and no controlled substances.